Peer-Reviewed Publications

    In vitro systems toxicology-based assessment of the potential modified risk tobacco product CHTP 1.2 for vascular inflammation- and cytotoxicity-associated mechanisms promoting adhesion of monocytic cells to human coronary arterial endothelial cells

    Poussin, C.; Laurent, A.; Kondylis, A.; Marescotti, D.; van der Toorn, M.; Guedj, E.; Goedertier, D.; Acali, S.; Pak, C.; Dulize, R.; Baumer, K.; Peric, D.; Maluenda, E.; Bornand, D.; Suarez, I. G.; Schlage, W. K.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.

    Published
    Jul 17, 2018
    DOI
    10.1016/j.fct.2018.07.025
    PMID
    30026091
    Link to publication
    Topic
    Summary

    Cigarette smoking causes cardiovascular diseases. Heating tobacco instead of burning it reduces the amount of toxic compounds in the aerosol and may exert a reduced impact on health compared with cigarette smoke. Aqueous extract from the aerosol of a potential modified risk tobacco product, the Carbon Heated Tobacco Product (CHTP) 1.2, was compared in vitro with aqueous extract from the smoke of a 3R4F reference cigarette for its impact on the adhesion of monocytic cells to artery endothelial cells. Human coronary arterial endothelial cells (HCAEC) were treated for 4h with conditioned media from monocytic Mono Mac 6 (MM6) cells exposed to CHTP1.2 or 3R4F extracts for 2h or directly with those extracts freshly generated. In vitro monocyte-endothelial cell adhesion was measured concomitantly with inflammatory, oxidative stress, cytotoxicity, and death markers. Furthermore, transcriptomics analyses enabled to quantify the level of perturbation in HCAECs, and provide biological interpretation for the underlying molecular changes following exposure to 3R4F or CHTP1.2 extract. Our systems toxicology study demonstrated that approximately 10-15-fold higher concentrations of the CHTP 1.2 aerosol extract were needed to elicit similar effects as the 3R4F smoke extract on cardiovascular disease-relevant inflammation and cytotoxicity-related mechanisms and markers investigated in vitro.

    Related Publications

    Impact of cigarette smoke and Modified Risk Tobacco Products (MRTPs) on DNA methylation

    Pre-clinical Toxicology Systems Toxicology

    Effects Of Cigarette Smoke On The High Fat Diet-Induced ApoE-/- Mouse Model Of Diabetic Atherosclerosis

    Pre-clinical Toxicology Systems Toxicology

    Chronological Changes in BEAS-2B Cells Chronically Exposed to Cigarette Smoke Total Particulate Matter

    Pre-clinical Toxicology Systems Toxicology

    Quantitative proteomics analysis using 2D-PAGE to investigate the effects of cigarette smoke and aerosol of a prototypic modified risk tobacco product on the lung proteome in C57BL/6 mice

    Pre-clinical Toxicology Systems Toxicology

    Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis

    Pre-clinical Toxicology Systems Toxicology

    The response of human nasal and bronchial organotypic tissue cultures to repeated whole cigarette smoke exposure

    Pre-clinical Toxicology Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.